Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. (SHE:301584)
17.70
-0.47 (-2.59%)
At close: Nov 17, 2026
SHE:301584 Revenue
Shanghai C&D INNOSTIC Medical Technology Group had revenue of 4.52B CNY in the quarter ending March 31, 2026, with 1.96% growth. This brings the company's total for the last twelve months to 19.44B, up 7.64% year-over-year. In the year 2025, Shanghai C&D INNOSTIC Medical Technology Group had annual revenue of 19.43B with 8.41% growth. That makes Shanghai C&D INNOSTIC Medical Technology Group the 3,902nd largest company in the world by revenue and 498th in China.
Revenue (ttm)
19.44B
Revenue Growth
+7.64%
P/S Ratio
0.39
Revenue / Employee
9.19M
Employees
2,115
Market Cap
7.46B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:301584 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.43B | 1.51B | 8.41% |
| Dec 31, 2024 | 17.92B | 2.48B | 16.06% |
| Dec 31, 2023 | 15.44B | 3.56B | 29.97% |
| Dec 31, 2022 | 11.88B | 1.86B | 18.54% |
| Dec 31, 2021 | 10.02B | 1.48B | 17.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jointown Pharmaceutical Group | 171.51B |
| C.Q. Pharmaceutical Holding | 80.51B |
| China National Accord Medicines Corporation | 73.36B |
| China National Medicines Corporation | 53.69B |
| China Meheco Group | 34.46B |
| Guangxi LiuYao Group | 21.31B |
| Liaoning Cheng Da | 8.41B |
| Qingdao Baheal Medical INC. | 7.10B |